“EISAI SUBMITS APPLICATIONS FOR ANTICANCER AGENT HALAVEN® SIMULTANEOUSLY IN JAPAN, U.S. AND EUROPE SEEKING NEW INDICATION AS TREATMENT FOR SOFT TISSUE SARCOMA
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted applications to regulatory authorities in Japan, the United States and Europe (MHLW, FDA and EMA respectively) seeking an additional indication for its in-house developed anticancer agent Halaven® (eribulin mesylate) as a treatment for soft tissue sarcoma.” (From Eisai Homepage)
http://www.eisai.com/news/news201553.html